Will be used for the production of active pharmaceutical ingredients for biopharmaceuticals
Danish diabetes drug specialist Novo Nordisk has acquired a manufacturing facility in West Lebanon, New Hampshire, US, from Olympus Biotech for an undisclosed sum.
The facility was established in 1989, expanded in 2003–2006 and was acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.
Novo Nordisk says it will use the facility for production of active pharmaceutical ingredients primarily for its portfolio of biopharmaceuticals.
Some of the plant's former employees have been offered jobs and initially will focus on planning the future set-up of the plant. Final plans will determine the potential and timing for increasing staffing levels in the future.
The two companies have agreed not to disclose any further details of the transaction.